Generic launch was impossible, says Impax
Impax has argued in court that although it had bottled $1.5 million worth of Oxymorphone by June 2010, it wasn’t prepared to launch at risk because the company hadn’t made enough of the drug to last a month in the market.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10